Ultragenyx Pharma (RARE) Misses Q1 EPS by 79c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update
May 4, 2021 4:01 PM EDTFirst quarter 2021 total revenue of $99.4 million and Crysvita1 revenue to Ultragenyx of $42.1 million
2021 Crysvita revenue in Ultragenyx territories1 guidance of $180 million to $190 million reaffirmed
Strong Dojolvi launch continues with approximately 180 patients on reimbursed commercial therapy in the United States
NOVATO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the... More
